| Bioactivity | Anticancer agent 135 (compound 26h) is a potent androgen receptor (AR) antagonist. Anticancer agent 135 can effectively block AR nuclear translocation and inhibit AR/AR-V7 heterodimerization, thereby inhibiting downstream gene transcription. Anticancer agent 135 displays potent robust efficacy in prostate cancer xenograft models[1]. |
| Name | Anticancer agent 135 |
| Formula | C23H21F3N4OS |
| Molar Mass | 458.50 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Xiujin Chang, et al. Discovery of thiohydantoin based antagonists of androgen receptor with efficient degradation for the treatment of prostate cancer. Eur J Med Chem. 2023 Sep 5;257:115490. |
Anticancer agent 135
CAS: F: C23H21F3N4OS W: 458.50
Anticancer agent 135 (compound 26h) is a potent androgen receptor (AR) antagonist. Anticancer agent 135 can effectively
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.